A Practical Approach to Cardiac Anesthesia (Practical Approach Series) 5th Ed.

18 Blood Transfusion

Colleen G. Koch

KEY POINTS

 1. Both anemia and transfusion carry significant risks. Balancing these risks is the key to appropriate blood transfusion decisions.

 2. Despite published guidelines about transfusion, clinical transfusion practice still varies substantially among clinicians and centers and often falls outside recommended guidelines.

 3. In addition to well-established acute immunologic and infection transmission complications, RBC transfusion in cardiac surgical patients has more recently been associated with increased mortality and infectious complications.

 4. Transfusion-related acute lung injury (TRALI) is the most frequent cause of mortality complicating blood transfusion. Among blood components, fresh frozen plasma (FFP) may carry the highest risk for TRALI.

 5. RBC storage duration has been associated with increased morbidity and mortality in cardiac surgery.

 6. One retrospective study associated platelet transfusion with increased morbidity and mortality in cardiac surgery, but several other studies did not.

 7. FFP transfusion alone has been associated with increased risk for perioperative mortality, infection, multiorgan failure, and acute respiratory distress syndrome.

“BLOOD TRANSFUSION IS LIKE MARRIAGE: it should not be entered upon lightly, unadvisedly or wantonly or more often than is absolutely necessary.”

R. Beale R [1]

1

I. Background

Competing risks form the core of perioperative transfusion. We are faced with tangible risks of patient complications from low hemoglobin values, yet we face different but equally real risks when we expose patients to red blood cell (RBC) transfusion. The risks of both anemia and transfusion vary with patient comorbidities, degree of and ability to tolerate anemia, and surgical procedure. In the dynamic milieu of the operating rooms, clinicians caring for cardiovascular surgical patients face challenging transfusion decisions daily. There are no measures that can definitively direct RBC transfusion decisions, rather clinical judgment using the balance of perceived risk versus benefit guides individual transfusion decisions. Given this background, the substantial variability of RBC transfusion even within a single institution becomes understandable [2,3].

2

   A. Variability in practice patterns often serves as the impetus for evidence-based guidelines that are intended to reconcile disparate evidence. Recent work highlights the low level of practitioner adoption of published transfusion practice guidelines. Although a number of factors contributed to low physician adoption, the authors principally attributed it to the low level of evidence provided to support guideline recommendations [4]. Others have also reported limited evidence basis for use of RBC transfusion [5].

   B. The reports on complications of RBC transfusion have increased scrutiny of transfusion practices in the last decade; however, economics and anticipated changes in population demographics have also driven change. A population-based cross-sectional study projected a growing gap between future demand and donation of blood with substantial increases in blood demand related to the changes in population demographics [6]. A recent editorial noted that 55% to 60% of the blood products transfused in the United States are given to the patients over 65 yrs old, and projected that this population will increase by 36% in the next 10 yrs, whereas the principal blood donor population will only increase by 5% over the same period. These demographic changes will influence medical practices and surgical procedures while increasing demand for blood products [7].

II. Red Blood Cell Transfusion and Adverse Outcomes

RBC units contain red cells separated from whole blood by centrifugation or by apheresis [8] (Table 18.1). Isbister and colleagues reported on the abundance of data supporting morbidity risk associated with transfusion, yet noted transfusion remains “ingrained” in current medical practice almost as a “default” position [9]. Furthermore, establishing causation between RBC transfusion and morbidity is difficult because of the potential for confounding in cohort study designs. Some argue that the etiology of poor outcomes relates to the “sicker” patient who receives a transfusion rather than the RBC product itself. Although it is difficult to discern whether morbidity is patient or transfusion related, either way RBC transfusion remains a significant risk factor for poor outcome [9].

Table 18.1 Fast facts: red blood cells from American Red Cross compendium8

3

   A. Morbidity and Mortality Risk

     1. RBC transfusion has been associated with a number of immunologic complications such as hemolytic, anaphylactoid and febrile transfusion reactions, graft-versus-host disease, and transfusion of viral and bacterial contaminants [8]. RBC transfusion has been associated with an increased risk for a number of complications following surgery. In an isolated coronary artery bypass grafting (CABG) population of over 11,000 patients, RBC transfusion was associated with a dose-dependent increased risk for morbidity: More postoperative cardiac complications, prolonged postoperative ventilator support, more infectious complications, renal failure, and higher in-hospital mortality (Fig 18.1). Following risk adjustment for known confounders, RBC transfusion remained a significant risk factor for poor clinical outcomes. The effect of transfusion on morbidity was dose-dependent, that is, more RBC units transfused incrementally increased risk (Fig. 18.2). A number of factors were related to patients’ need for transfusion: Demographics such as older age, history of peripheral vascular disease and chronic obstructive pulmonary disease, clinical presentation such as emergency surgery, and surgical factors such as reoperation and prolonged aortic clamp time [10].

Figure 18.1 Forest plot displays the unadjusted and adjusted odds ratios and their 95% confidence limits for seven postoperative morbid outcomes when comparing patients undergoing cardiac surgery who did and did not receive an RBC transfusion. (Reproduced with permission from Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608–1616.)

Figure 18.2 Panel of six morbidity outcomes displays the dose–response relationship between increasing number of RBC units transfused and risk for postoperative morbidity outcomes. The dashed lines represent the patient who received only RBC transfusion; the solid lines represent those patients who received platelet transfusion as well. (Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608–1616.)

      2. Kudivalli and colleagues examined the effect of RBC transfusion on 30-day and 1-yr mortality in cardiac surgical patients. Risk-adjusted mortality at 30 days and 1 yr was significantly higher for patients who were transfused. Risk factors for RBC transfusion were lower hemoglobin, lower body mass index, female gender, renal dysfunction, reoperation and use of cardiopulmonary bypass [11]. An investigation of long-term survival in over 10,000 isolated CABG patients reported a risk-adjusted reduction in survival both early and late to 10 yrs for patients who received perioperative RBCs. This relationship was dose dependent and was sustained after adjustment for confounding variables known to increase mortality risk following isolated CABG [12].

      3. A recent investigation examined over 9,000 patients who underwent cardiac surgical procedures and who were and were not exposed to 1 to 2 unit RBC transfusion. Patients who received RBCs had a 16% increased hazard for reduced survival 6 mos following the cardiac surgery. The authors emphasized the decision to transfuse even these small volumes of RBCs placed patients at significant risk for mortality [13]. Others have also reported reduced survival in cardiac surgical patients receiving RBC transfusions [14].

      4. Murphy and colleagues examined outcomes after RBC transfusion in over 8,500 cardiac surgical patients. There was a strong association between transfusion and postoperative infectious complications, early and late mortality, length of stay, and overall hospital costs. The authors reported a significant risk for composite ischemic outcome noting this was somewhat counterintuitive as transfusion is intended to restore tissue oxygenation [15].

      5. Banbury and colleagues identified risk factors for the occurrence of postoperative infectious complications following cardiac surgery in a population of over 15,000 patients in which over 50% of patients were transfused. There was a dose-dependent effect of increasing RBC transfusion and increased prevalence of postoperative septicemia/bacteremia and superficial and deep sternal wound infections. These authors appropriately noted that transfusion occurred in patients who were the sickest; yet, even following risk adjustment, transfusion contributed to postoperative infectious risk [16].

      6. Transfusion of RBCs plays a role in augmenting the inflammatory response to cardiac surgery. Development of atrial fibrillation is a common and costly complication following cardiac surgery that links partially an inflammatory mechanism. In a population of 5,841 cardiac surgical patients, transfusion of RBCs increased the prevalence of postoperative atrial fibrillation. The analysis was risk-adjusted for traditional risk factors associated with development of atrial fibrillation such as demographics, history of atrial fibrillation, preoperative medications, and perioperative variables. RBC transfusion increased risk for postoperative atrial fibrillation in both on- and off-cardiopulmonary bypass procedures [17].

      7. A recent publication by Tuinman and colleagues related complications of transfusion during cardiac surgery to activation of pulmonary inflammation and coagulation [18].

4

     8. The Food and Drug Administration’s (FDA) summary of fatalities related to transfusion for fiscal year 2009 listed transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) among the more common complications associated with transfusion (Fig. 18.3). TRALI has consistently been one of the most common causes of death associated with transfusion [19]. TRALI, which is primarily a clinical diagnosis, can vary from mild to severe. It is defined by presence of hypoxemia and specific X-ray findings that occur within a certain time following transfusion. The purported mechanism for TRALI involves activation of neutrophils with endothelial injury and resultant pulmonary edema [2022].

Figure 18.3 A report from the Food and Drug Administration illustrates the transfusion-related fatalities by complication for fiscal years 2005–2009. For each year TRALI represents the most frequently reported cause of transfusion-related mortality [19]. TRALI, transfusion-related acute lung injury; HTR (non-ABO), hemolytic transfusion reactions unrelated to ABO incompatibility; HTR (ABO), hemolytic transfusion reactions related to ABO incompatibility; TACO, transfusion-associated circulatory overload; FY05, Fiscal Year 2005 (similarly for other FYs).

      9. A recent investigation noted that TRALI, a diagnosis of exclusion, can be difficult to diagnose in patients undergoing cardiac surgery. The authors reported greater pulmonary morbidity in the postoperative period for patients transfused with RBCs and FFP; this pulmonary morbidity may have been related to TRALI, TACO, or both. Nevertheless, transfusion of either RBCs or FFP was independently associated with pulmonary morbidity in the postoperative period [23].

     10. Stokes and colleagues recently examined the influence of bleeding-related complications, use of blood products, and costs in a population of inpatient surgical services. They recognized that inadequate surgical hemostasis leads to bleeding complications as well as to transfusion. The authors were able to rank incremental cost per hospitalization associated with bleeding-related complications and adjusted for covariates. Their findings support further need for implementation of blood conservation strategies [24].

     11. Bleeding complications and the associated need for reoperation in cardiac surgery are associated with increased morbidity. Recent work attempted to delineate whether increased morbidity risk for reoperation was related to the reoperation, blood transfusion, or both. The patients who underwent reoperation had greater subsequent morbidity, increased resource utilization, and higher in-hospital mortality even after risk adjustment [25] (Fig. 18.4).

Figure 18.4 Predicted probability of operative mortality stratified on reoperation for bleeding and RBC transfusion. RBC transfusion and reoperation for bleeding were associated with increased mortality. (Reproduced with permission from Vivacqua A, Koch CG, Yousuf AM, et al. Morbidity of bleeding after cardiac surgery: Is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg. 2011;91:1780–1790.)

     12. A recent investigation in non-cardiac thoracic surgical patients reported worse postoperative outcomes in patients who received 1 to 2 unit RBC transfusions. The negative effect of transfusion was dose dependent and was associated with increased morbidity and resource utilization. The authors urged clinicians to be cautious in transfusing patients for mild degrees of anemia [26].

     13. Grimshaw and colleagues emphasize that the use of RBCs has not been scrutinized using current methods for assessing efficacy and safety, and that mechanisms for the observed complications are not well understood. They suggest that RBC transfusion-associated inflammation and thrombosis may be related to RBC storage [27].

   B. Red Blood Cell Storage Duration

Changes in RBC product with increasing storage are well described and include alterations in RBC structural shape and in biochemical properties. Implications of these time-dependent changes may contribute to adverse clinical outcomes associated with RBC transfusion. However, clinical and experimental animal studies have reported inconsistent findings [2830].

      1. A group of investigators examined age of RBC products at the time of transfusion to gain an understanding of the age of RBC products used. Approximately one-third of RBC units transfused were stored longer than 3 wks storage duration, and for blood groups AB negative and A negative, more than 60% of total number of units transfused were older than 3 wks storage duration [31].

      2. Survival of red cells following transfusion is an important variable as it relates to the ability of red cells to perform their intended use. The FDA currently allows donor RBCs stored in ADSOL to have a shelf life of 42 days. The set time limit relates to a requirement for 75% of RBCs to remain in circulation 24 hrs after transfusion, without regard to their functional state. With fresh blood, RBC survival is approximately 90% 24 hrs post-transfusion. As storage duration increases, 24-hr survival (i.e., circulatory retention) rate decreases; however, it must be at least 75% during the approved life of the product [32,33].

     3. Laboratory Investigation

        a. As storage time increases, RBCs degrade in structural shape, aggregability, and metabolic function. The entire host of changes is referred to as the “storage lesion,” which contributes to limited post-transfusion RBC survival and potentially to impaired oxygen delivery via the microcirculation. The storage lesion may contribute to the morbidity associated with RBC transfusion [34,35].

        b. A number of biochemical changes that occur over time in stored RBCs product have been well described. S-nitrosothiol (SNOs) levels change 2 to 3 hrs after collection; changes occurring after several days of storage progressive increases in lactate, potassium, and free hemoglobin and a decrease in pH [35]. Storage-induced reduction in RBC membrane structural integrity (reduced deformability and increased fragility) is thought to be related to intra-RBC energy source depletion. Release of cell-free hemoglobin and microparticles (MPs) can lead to increased consumption of nitric oxide (NO) [36]. Some investigators have proposed insufficient NO bioavailability as an explanation for the increased morbidity and mortality observed after transfusion [37,38].

        c. Relevy and colleagues showed that routine cold storage damaged RBC membranes to increase stiffness, thereby potentially impairing flow properties. A continuous reduction in deformability was noted, ultimately producing rigid cells at the end of the storage period. The percentage of undeformable cells increased continuously starting as early as 2 wks after RBC collection. Increased RBC adherence was also noted. These findings suggest that transfusion of rheologically impaired RBCs might introduce morbidity risk, perhaps particularly to patients with cardiovascular disease [39].

        d. In an animal model, Rigamonti and colleagues suggested that stored blood has a reduced capacity to deliver oxygen to brain tissue. They reported that fresh blood better restores cerebral oxygen delivery and tissue oxygen tension than stored blood does [40]. Recent studies suggest that stored RBCs may contribute to reported morbidity complications via release of RBC-derived MPs, which may facilitate thrombosis and lung injury [4143].

5

     4. Clinical Investigation

Clinical studies examining the role of RBC storage duration on patient outcomes report inconsistent findings, yet many have small sample size with heterogeneous patient populations. A large investigation in cardiac surgery reported an increased risk of postoperative complications and higher mortality in patients who were transfused RBCs with prolonged storage. In total 2,800 patients received RBCs with 14 days storage or less and 3,130 patients received RBC units with greater than 14 days storage. Risks for mortality, postoperative ventilatory support beyond 72 hrs, renal failure, sepsis, and composite adverse outcome were all higher in patients receiving older blood. Following risk adjustment, composite adverse outcome and lower survival were still found in patients who received “older” RBCs [30] (Fig. 18.5). A recent investigation in cardiac surgery reported a higher prevalence of new renal complications and length of hospital stay in patients receiving older RBCs [44].

Figure 18.5 Kaplan–Meier estimates of survival and death for patients given exclusively newer blood (stored for 14 days or less; squares) and patients given exclusively older blood (stored more than 14 days; circles). Survival was lower for patients who received older blood as compared to those receiving newer blood, especially during the initial follow-up period. Inset shows the same data presented as mortality at each time interval rather than cumulative survival. (Reproduced with permission from Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–1239.)

        a. In trauma settings, transfusion of older RBCs is associated with increased incidences of infection [45], deep vein thrombosis, death [46,47], and multisystem organ failure [48]. In cohorts of critically ill intensive care unit (ICU) patients, exposure to older RBCs was independently associated with increased mortality, and this response may be proportionate to the number of units transfused [4952].

        b. Of note, there are investigations reporting similar patient outcomes with fresh blood and with blood of increasing storage duration. Findings from Walsh and colleagues did not support the use of fresh RBCs in critically ill ICU patients. They reported transfusion of stored leukodepleted RBCs had no adverse effects on gastric tonometry or global indexes of tissue oxygenation [53]. In a group of 897 patients, Leal-Noval and colleagues reported that prolonged storage did not increase overall morbidity risk in cardiac surgery, but RBCs stored longer than 28 days might increase the risk for pneumonia [54]. An exceedingly small investigation recently reported that the number of RBC units, but not the storage duration, was associated with poor outcomes. Only 68 patients received RBCs with 14 days storage or less and none had a mortality event or prolonged ventilation beyond 72 hrs [55]. Others have also reported no effect of RBC storage duration on patient morbidity [29,56].

        c. Even if one should accept that prolonged RBC storage duration indisputably increases risk, in the absence of a change in the acceptable “shelf life” of collected RBCs there is little that practicing clinicians can do to address this risk.

III. Component Therapy

   A. Restrictive RBC transfusion practices have become a standard of care; yet, evidence-based indications for the use of blood component therapy such as FFP and platelet concentrate transfusion have been more limited [57]. Following donation, whole blood is separated into components, which are stored at different temperatures. While RBCs can be stored up to 42 days at 1 to 6°C , platelets are stored at room temperature with a shorter storage duration of 5 days. Plasma and cryoprecipitate can be stored frozen for 1 yr [58].

    Use of predetermined ratios of component therapy to RBCs has gained increased attention as a result of recent research in military and civilian trauma resuscitation. These investigations focus on earlier and increased use of component therapy (i.e., ratios of 1:1:1 of RBC to FFP to platelets). This strategy is thought to prevent dilutional and traumatic coagulopathy [59]. Liumbruno and colleagues provided detailed recommendations for transfusion of FFP and platelets in a number of clinical settings [60]. Mitra et al. found an increased initial survival in association with higher FFP/RBC ratios. However, those authors also noted that this association is difficult to interpret because of an inherent survival bias [61].

   Sperry and colleagues associated the FFP to RBC ratios 1:1.5 with lower mortality after massive transfusion. In a population of patients with serious blunt injury and who required greater than or equal to 8 units of RBCs, survival was better; yet, the risk of acute respiratory distress syndrome was higher [62]. While there is retrospective evidence to support increased survival with more aggressive use of plasma and platelets in massive transfusion, the efficacy of such practice has not been established with prospective, randomized studies [63,64].

   B Platelet Therapy (Table 18.2)

  Platelets are stored at 20 to 24°C and have a shelf life limited to 5 days [58]. General recommendations for platelet therapy stress that platelet transfusion cannot be based simply on platelet count. In general, for major surgical procedures or during massive transfusion (e.g., one or more blood volumes has been replaced) a platelet count of at least 50,000/μL is recommended [60]. A standard dose of platelets for adults is approximately one unit per 10 kg body weight. In general, transfusion of six units of platelets harvested from whole blood increases the platelet count by approximately 30,000/μL [65] (Table 18.2). This platelet “dose” corresponds roughly with that provided by a single-donor plateletpheresis.

6

     1. Specific morbidity associated with platelet transfusion remains unclear. TRALI [19] has been associated with platelet transfusion more than other morbidities. In a large investigation of over 11,000 patients, Karkouti and colleagues reported no increased risk for adverse outcomes in cardiac surgical patients who received platelet transfusions [66]. Similarly, McGrath and colleagues studied over 30,000 cardiac surgical patients and found no association between platelet transfusion and patient morbidity. Analysis was performed on patients with and without concomitant RBC transfusion and the results were similar. The patients who received platelet transfusions were considered higher risk based on comorbidity, but even after risk adjustment they experienced similar outcomes as the patients who did not receive platelet transfusion. The authors concluded that platelet transfusion in the setting of microvascular bleeding did not increase morbidity [67].

Table 18.2 Fast facts: platelets from American Red Cross compendium8

      2. One retrospective investigation of cardiac surgical patients associated higher stroke risk and mortality with platelet transfusion. These data were extracted from a clinical trial on aprotinin [68].

     3. Similar to RBCs, storage leads to changes in platelet structural and biochemical properties over time. A recent study found no increase in short-term adverse outcomes with increasing platelet storage time [69]. These authors and others reviewed current challenges of maintaining adequate platelet inventory with the limit of 5 days storage and also described the platelet storage lesion and the interesting controversy surrounding the proposed extension of platelet storage to 7 days (e.g., the increased risk for bacterial contamination over time is well described) [6974].

   C. Fresh Frozen Plasma (Table 18.3)

FFP is human donor plasma and refers to plasma that is separated and frozen at temperatures of –18°C within 8 hrs of collection; frozen plasma-24 (FP-24) refers to plasma separated and frozen at –18°C within 24 hrs of collection. FFP from a collection of whole blood has a volume of ~300 mL and can be stored up to 1 yr. Both products contain necessary plasma coagulation factors which are maintained after thawing and storage at 1 to 6°C for up to 5 days. In general, the dose of FFP is 10 to 20 mL/kg [58,60,75]. FFP should be ABO-compatible but does not require crossmatching [76].

Table 18.3 Fast facts: fresh plasma from American Red Cross compendium8

     1. Excessive blood loss, coagulation factor consumption, and specific deficiencies in coagulation factors are among a number of factors that can lead to inadequate hemostasis and the need for an FFP transfusion, particularly when a concentrate is unavailable [76]. In the setting of massive transfusion, it is well recognized that the use of crystalloids, colloids, and RBCs can lead to a dilutional coagulopathy, and that these conditions can potentially lead to disseminated intravascular coagulation [60,77]. A number of publications address limited adherence to published guidelines for FFP transfusion [78,79]. In the setting of excessive surgical bleeding, it has been suggested that clinicians guide their FFP use and dosing by point-of-care testing coagulation studies rather than by preset formulas(see also Chapter X) [79].

      2. Interestingly, in patients with minimally prolonged international normalized ratio (INR (less than 1.6), Holland and Brooks reported that FFP transfusion failed to change the INR; INR decreased only with the treatment of the disease causing the increase in INR [78]. Prophylactic use of FFP is not supported by evidence from good quality randomized controlled trials (RCTs). The strongest RCT evidence indicates that prophylactic plasma for transfusion is not effective across a range of clinical settings [80].

7

      3. In addition to the risk for TRALI, FFP transfusion carries the risk for other morbidities. Bilgin and colleagues analyzed data from two RCTs about the effects of platelet and FFP transfusion on postoperative infections, length of ICU stay, and all-cause mortality. Perioperative FFP transfusion was associated with all-cause mortality [81]. Similarly, Watson and colleagues reported greater risk for multisystem organ failure and acute respiratory distress syndrome with FFP transfusion in the trauma setting [82]. Others also have associated an increase in adverse patient outcomes with FFP administration [83].

   D. Cryoprecipitate (Table 18.4)

One bag of cryoprecipitate contains 10 to 15 mL of insoluble protein. When FFP is thawed for 24 hrs at 1 to 6°C, high molecular weight proteins separate out from the plasma; this can be frozen at –18°C for up to 1 yr. Cryoprecipitate contains Factors I (fibrinogen), VIII, XIII, von Willebrand Factor, fibronectin, and platelet MPs. It is most commonly used as a concentrated source of fibrinogen. A common indication is hypofibrinogenemia in the setting of hemorrhage, yet its role in management of hemostasis remains unclear. Depending upon the weight of the recipient, 10 bags of cryoprecipitate will increase plasma fibrinogen by 70 to 100 mg/dL [58,75,76,84].

Table 18.4 Fast facts: cryoprecipitate, from American Red Cross compendium8

IV. Conclusion

While transfusion is a necessary treatment strategy for selected patients, it is associated with a number of morbidity risks (as is anemia). Recent work suggests moving from the current blood banking, “supply-centric” perspective to a “patient-centric” approach [9]. Implementation of institutional blood management protocols enhances practitioner knowledgebase and the consistency of transfusion practices (see Chapter 19) while inducing a more conservative approach to blood product usage.

REFERENCES

 1. Beale RJ. The rational use of blood. Aust N Z J Surg. 1976;46:309–313.

 2. Bennett-Guerrero E, Zhao Y, O’Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA. 2010;304:1568–1575.

 3. Karkouti K, Wijeysundera DN, Beattie WS, et al. Variability and predictability of large-volume red blood cell transfusion in cardiac surgery: a multicenter study. Transfusion. 2007;47:2081–2088.

 4. Likosky DS, FitzGerald DC, Groom RC, et al. Effect of the perioperative blood transfusion and blood conservation in cardiac surgery clinical practice guidelines of the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists upon clinical practices. Anesth Analg. 2010;111:316–323.

 5. Wilkinson KL, Brunskill SJ, Doree C, et al. The clinical effects of red blood cell transfusions: an overview of the randomized controlled trials evidence base. Transfusion Med Rev. 2011;25:145–155 e2.

 6. Greinacher A, Fendrich K, Brzenska R, et al. Implications of demographics on future blood supply: a population-based cross-sectional study. Transfusion. 2011;51:702–709.

 7. Benjamin RJ, Whitaker BI. Boom or bust? Estimating blood demand and supply as the baby boomers age. Transfusion. 2011;51:670–673.

 8. American Red Cross. A Compendium of Transfusion Practice Guidelines. 1st ed. 2010:1–112.

 9. Isbister JP, Shander A, Spahn DR, et al. Adverse blood transfusion outcomes: establishing causation. Transfusion Med Rev. 2011;25:89–101.

10. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med.2006;34:1608–1616.

11. Kuduvalli M, Oo AY, Newall N, et al. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg.2005;27:592–598.

12. Koch CG, Li L, Duncan AI, et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006;81:1650–1657.

13. Surgenor SD, Kramer RS, Olmstead EM, et al. The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. Anesth Analg. 2009;108:1741–1746.

14. Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002;74:1180–1186.

15. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544–2552.

16. Banbury MK, Brizzio ME, Rajeswaran J, et al. Transfusion increases the risk of postoperative infection after cardiovascular surgery. J Am Coll Surg. 2006;202:131–138.

17. Koch CG, Li L, Van Wagoner DR, et al. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. Ann Thorac Surg. 2006;82:1747–1756.

18. Tuinman PR, Vlaar AP, Cornet AD, et al. Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Crit Care. 2011;15:R59.

19. FDA. Fatalities Reported to the FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2009. 2009.

20. Toy P, Lowell C. TRALI – definition, mechanisms, incidence and clinical relevance. Best Pract Res. 2007;21:183–193.

21. Gilliss B, Looney MR. Experimental models of transfusion-related acute lung injury. Transfusion Med Rev. 2011;25(suppl 1): 1–11.

22. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108:2455–2462.

23. Koch C, Li L, Figueroa P, et al. Transfusion and pulmonary morbidity after cardiac surgery. Ann Thorac Surg. 2009;88:1410–1418.

24. Stokes ME, Ye X, Shah M, et al. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Serv Res. 2011;11:135.

25. Vivacqua A, Koch CG, Yousuf AM, et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg. 2011;91:1780–1790.

26. Ferraris VA, Davenport DL, Saha SP, et al. Intraoperative transfusion of small amounts of blood heralds worse postoperative outcome in patients having noncardiac thoracic operations. Ann Thorac Surg. 2011;91:1674–1680.

27. Grimshaw K, Sahler J, Spinelli SL, et al. New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells. Transfusion.2011;51:874–880.

28. Raat NJ, Ince C. Oxygenating the microcirculation: the perspective from blood transfusion and blood storage. Vox Sang. 2007;93:12–18.

29. Yap CH, Lau L, Krishnaswamy M, et al. Age of transfused red cells and early outcomes after cardiac surgery. Ann Thorac Surg. 2008;86:554–559.

30. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–1239.

31. Raat NJ, Verhoeven AJ, Mik EG, et al. The effect of storage time of human red cells on intestinal microcirculatory oxygenation in a rat isovolemic exchange model. Crit Care Med. 2005;33:39–45; discussion 238–239.

32. Simon E. Adenine in Blood banking. Tranfusion. 1997;17:317–325.

33. Hamasaki N, Yamamoto M. Red blood cell function and blood storage. Vox Sang. 2000;79:191–197.

34. Chin-Yee IH, Arya N, d’ Almeida M. The Red cell storage lesion and its implication for transfusion. Transfus Sci. 1997;18:447–458.

35. Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci USA. 2007;104:17063–17068.

36. Kim-Shapiro DB, Lee J, Gladwin MT. Storage lesion: role of red blood cell breakdown. Transfusion. 2011;51:844–851.

37. Roback JD, Neuman RB, Quyyumi A, et al. Insufficient nitric oxide bioavailability: a hypothesis to explain adverse effects of red blood cell transfusion. Transfusion. 2011;51:859–866.

38. Weinberg JA, Barnum SR, Patel RP. Red blood cell age and potentiation of transfusion-related pathology in trauma patients. Transfusion. 2011;51:867–873.

39. Relevy H, Koshkaryev A, Manny N, et al. Blood banking-induced alteration of red blood cell flow properties. Transfusion. 2008;48:136–146.

40. Rigamonti A, McLaren AT, Mazer CD, et al. Storage of strain-specific rat blood limits cerebral tissue oxygen delivery during acute fluid resuscitation. Br J Anaesth. 2008;100:357–364.

41. Jy W, Ricci M, Shariatmadar S, et al. Microparticles in stored red blood cells as potential mediators of transfusion complications. Transfusion. 2011;51:886–893.

42. Sweeney J, Kouttab N, Kurtis J. Stored red blood cell supernatant facilitates thrombin generation. Transfusion. 2009;49:1569–1579.

43. Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med. 2003;31:S687–S697.

44. Sanders J, Patel S, Cooper J, et al. Red blood cell storage is associated with length of stay and renal complications after cardiac surgery. Transfusion. 2011;51:2286–2294.

45. Offner PJ, Moore EE, Biffl WL, et al. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg. 2002;137:711–716; discussion 6–7.

46. Spinella PC, Carroll CL, Staff I, et al. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care. 2009;13:R151.

47. Weinberg JA, McGwin G, Jr., Griffin RL, et al. Age of transfused blood: an independent predictor of mortality despite universal leukoreduction. J Trauma. 2008;65:279–282; discussion 82–84.

48. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg. 1999;178:570–572.

49. Pettila V, Westbrook AJ, Nichol AD, et al. Age of red blood cells and mortality in the critically ill. Crit Care. 2011;15:R116.

50. Gauvin F, Spinella PC, Lacroix J, et al. Association between length of storage of transfused red blood cells and multiple organ dysfunction syndrome in pediatric intensive care patients. Transfusion.2010;50:1902–1913.

51. Eikelboom JW, Cook RJ, Liu Y, et al. Duration of red cell storage before transfusion and in-hospital mortality. Am Heart J. 2010;159:737–743 e1.

52. Pettila V, Westbrook AJ, Nichol AD, et al. Age of red blood cells and mortality in the critically ill. Crit Care. 2011;15:R116.

53. Walsh TS, McArdle F, McLellan SA, et al. Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients? Crit Care Med.2004;32:364–371.

54. Leal-Noval SR, Jara-Lopez I, Garcia-Garmendia JL, et al. Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients. Anesthesiology. 2003;98:815–822.

55. McKenny M, Ryan T, Tate H, et al. Age of transfused blood is not associated with increased postoperative adverse outcome after cardiac surgery. Br J Anaesth. 2011;106:643–649.

56. van de Watering L, Lorinser J, Versteegh M, et al. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;46:1712–1718.

57. Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm? Crit Care Med. 2006;34:S170–S173.

58. Silvergleid A, Kleinman S, Landaw S. Preparation of Blood Components. UpToDate 2011; www.uptodate.com/contents/preparation-of-blood-components.

59. Jansen JO, Thomas R, Loudon MA, et al. Damage control resuscitation for patients with major trauma. BMJ. 2009;338:b1778.

60. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7:132–150.

61. Mitra B, Mori A, Cameron PA, et al. Fresh frozen plasma (FFP) use during massive blood transfusion in trauma resuscitation. Injury. 2010;41:35–39.

62. Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio >/ = 1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma. 2008;65:986–993.

63. Phan HH, Wisner DH. Should we increase the ratio of plasma/platelets to red blood cells in massive transfusion: what is the evidence? Vox Sang. 2010;98:395–402.

64. Stansbury LG, Dutton RP, Stein DM, et al. Controversy in trauma resuscitation: do ratios of plasma to red blood cells matter? Transfusion Med Rev. 2009;23:255–265.

65. Yuan S, Goldfinger D, Silvergleid A, et al. Clinical and Laboratory Aspects of Platelet Transfusion Therapy. UpToDate 2011; www.uptodate.com/contents/clinical-and-laboratory-aspects-of-platelet-transfusion.

66. Karkouti K, Wijeysundera DN, Yau TM, et al. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Can J Anaesth. 2006;53:279–287.

67. McGrath T, Koch CG, Xu M, et al. Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes. Ann Thorac Surg. 2008;86:543–553.

68. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004;44:1143–1148.

69. Welsby IJ, Lockhart E, Phillips-Bute B, et al. Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion. 2010;50:2311–2317.

70. Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfusion Med Rev. 1997;11:130–144.

71. Cauwenberghs S, van Pampus E, Curvers J, et al. Hemostatic and signaling functions of transfused platelets. Transfusion Med Rev. 2007;21:287–294.

72. Holme S. Storage and quality assessment of platelets. Vox Sang. 1998;74(suppl 2):207–216.

73. Kleinman S, Dumont LJ, Tomasulo P, et al. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion.2009;49:903–912.

74. Eder AF, Moroff G. Platelet storage and adverse transfusion outcomes: old platelets? Transfusion. 2010;50:2288–2291.

75. Stanworth S. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology. 2007:179–186.

76. May A, Manaker S, Wilson K. Use of Blood Products in the Critically Ill. UpToDate 2011;www.uptodate.com/contents/use-of-blood-products-in-the-critically-ill.

77. Hellstern P, Muntean W, Schramm W, et al. Practical guidelines for the clinical use of plasma. Thromb Res. 2002;107(suppl 1): S53–S57.

78. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006;126:133–139.

79. O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28.

80. Verghese SG. Elective fresh frozen plasma in the critically ill: what is the evidence? Crit Care Resusc. 2008;10:264–268.

81. Bilgin YM, van de Watering LM, Versteegh MI, et al. Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion. 2011;51(12):2603–2610.

82. Watson GA, Sperry JL, Rosengart MR, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma.2009;67:221–227; discussion 8–30.

83. Bochicchio GV, Napolitano L, Joshi M, et al. Outcome analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted study. World J Surg. 2008;32:2185–2189.

84. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev. 2009;23:177–188.